The Six-minute Walk Test (6MWT) for the Evaluation of Pulmonary Diseases

Document Type : Review Article


1 Pulmonologist, Cardio-Thoracic Surgery & Transplant Research Center, Emam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Pulmonologist, Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Cardiologist, Emam Reza, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Community Medicine Specialist, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Internist, Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


The six-minute walk test (6MWT) is a well-tolerated test which reflects daily activities and can be easily used in clinical practice. The 6MWT provides information about functional capacity, response to therapy and prognosis across a range of chronic cardiopulmonary conditions.
Moreover, the 6MWT is sensitive to the common therapies used for chronic obstructive pulmonary disease, such as pulmonary rehabilitation with supplemental oxygen, long-term use of inhaled corticosteroids and lung volume reduction surgery.
Several studies have investigated the role of 6MWT in the evaluation of pulmonary disease and cardiac disorders. This article aimed to review the significance of 6MWT in pulmonary disease


  1. Balke B. A simple field test for the assessment of physical fitness. Rep Civ Aeromed Res Inst US. 1963:18.
  2. McGavin CR, Gupta SP, McHardy GJR. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J. 1976;1(6013):822–3.
  3. Butland RJA, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982; 284:1607–8.
  4. Venkatesh N, Thanikachalam S, Satyanarayana Murthy J, Arun Maiya, Senthil Kumar T, Sridevi S. Six minute walk test: a literary review. Sri Ramachandra Journal of Medicine. 2011;4):30-4.
  5. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001; 119256–70.
  6. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166:111-7.
  7. Dourado VZ. Reference equations for the 6 – minute walk test in healthy individuals. Arq Bras Cardiol. 2011.
  8. Alameri H, Al-Majed S, Al-Howaikan A. Six-min walk test in a healthy adult Arab population. Respir Med. 2009;101041-6.
  9.    Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009; 39:495-501.
  10. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-       controlled trial of    inhaled fluticasone propionate in patients with COPD. Lancet. 1998; 351:773–80.
  11.  Weiner P, Magadle R, Berar-Yanay N, Davidovich A, Weiner M. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest 2000;118672–8.
  12. Criner GJ, Cordova FC, Furukawa S, Kuzma AM, Travaline JM, Leyenson V, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe COPD. Am J Respir Crit Care Med. 1999; 160:2018–27.
  13.  Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction of  mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.  JAMA. 1993; 270:1702–7.
  14. Demers C, McKelvie RS, Negassa A, Yusuf S, Investigators RPS. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J 2001; 142: 698–703.
  15. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000; 161:487–92.
  16. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27:589–95.
  17.  Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001; 17:647–52.
  18. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest. 1999; 116:1175–82.
  19. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168: 1084–90.
  20. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174:659–64.